New York, March 4, 2026, 15:06 EST — Regular session
Johnson & Johnson slipped roughly 0.7% Wednesday, even as the company announced its lupus drug candidate nipocalimab received Fast Track designation from the U.S. FDA. Shares traded at $245.07, down $1.68 in the afternoon session. PR Newswire
Johnson & Johnson slipped behind the broader rally, as the SPDR S&P 500 ETF climbed nearly 1% and a healthcare sector fund edged up. Investors are trying to figure out if recent pipeline wins are enough to balance a stock that’s acted as a defensive play for months.
The FDA’s Fast Track designation offers drugmakers a quicker route to approval for treatments addressing serious conditions lacking good options. Companies can expect closer contact with the agency and, sometimes, the chance to submit sections of their application as they’re ready—no need to hold everything back for one big filing. U.S. Food and Drug Administration
Johnson & Johnson is developing nipocalimab, an FcRn blocker aimed at reducing IgG antibodies that can trigger autoantibody diseases. The company is currently enrolling for its Phase 3 GARDENIA trial in active systemic lupus erythematosus. “Accelerating the delivery of an immunoselective therapy”—that’s how disease-area leader Leonard L. Dragone described the significance of the designation. For patients, “treatment options remain limited,” said Richard Furie, a rheumatologist at Northwell Health. According to J&J, Furie has worked with the company as a consultant, advisor and speaker. JNJ.com
Johnson & Johnson, headquartered in New Brunswick, New Jersey, has scheduled its first-quarter earnings call for April 14 at 8:30 a.m. ET. CEO Joaquin Duato and CFO Joseph Wolk are both set to speak. JNJ.com
Merck picked up roughly 0.6% and AbbVie advanced about 0.8%, but Pfizer ended flat. Against that backdrop, Johnson & Johnson’s shift stood out as more about the company than the pharma group as a whole.
Still, Fast Track is a far cry from a green light, and lupus drugs have stumbled late before, despite promising signals earlier on. Johnson & Johnson’s stock also isn’t free of legal clouds, as the company continues to battle longstanding talc lawsuits. Reuters
Johnson & Johnson is set to take the stage at the Barclays Global Healthcare Conference on March 10, providing investors with a chance to pick up any new insights, according to the company. JNJ.com
Next up: April 14, when the company unveils its first-quarter results and possibly sheds light on the anticipated timeline for its upcoming medicines to hit regulators’ desks.
